To the Editor,

Since the outbreak of the COVID-19 pandemic, growing attention has been paid to the emerging association between severe forms of novel coronavirus pneumonia and abnormalities in coagulation parameters, in particular elevated D-dimer and fibrin degradation product (FDP) levels, that seem to relate to a poor prognosis and are seen as potential predictors of acute thrombotic complications including Acute Pulmonary Embolism (APE) ([@bib0020]).

Although isolated reports exist about this issue ([@bib0010], [@bib0005]), its real incidence still remains unknown, possibly due to the preferential use of High-Resolution Computed Tomography (HR-CT) rather than Computed Tomography Pulmonary Angiography (CTPA) to demonstrate inflammatory parenchymal changes.

Herein, we present a series of eight confirmed cases of peripheral multifocal APE in a cohort of 20 hospitalized patients, who consecutively underwent CTPA between March 25 and April 21, 2020, because of abnormal D-dimer levels (\>1000 μg/L) and at least one among the following inclusion criteria: risk factors for APE, clinical signs of APE, severe pneumonia (requiring minimum oxygen support of 10 L/min and/or need for Non-Invasive Ventilatory Support, NIV).

The YEARS algorithm, Well\'s score, and revised Geneva score were applied, although CTPA was performed regardless of their results.

Characteristics of the study population (40% males, median age 58 years) are reported in [Table 1](#tbl0005){ref-type="table"} .Table 1Characteristics of 20 Patients with Covid-19 who performed a CTPA for suspected pulmonary embolism.Table 1CharacteristicsTotal (N = 20)Absence of Pulmonary Embolism (N = 12)Pulmonary Embolism (N = 8)p valueMedian Age (IQR) - yr62 (56--80)60 (53--63)78 (59--84).177Male Sex - n (%)8 (40)6 (50)2 (25).373Comorbidity- n (%) Arterial Hypertension11 (55)6 (50)5 (62).670 Atrial Fibrillation2 (10)02 (25).147 Cancer2 (10)2 (17)0.495 Diabetes Type II3 (15)1 (8)2 (25).537 Obesity5 (25)2 (16)3 (37).347 Chronic Kidney Failure4 (20)2 (17)2 (25).999 COPD1 (5)01 (12).400Signs and Symptoms around the time of Hospitalization - n (%) Fever19 (95)12 (100)7 (87).400 Cough11 (55)6 (50)5 (62).670 Dyspnea9 (45)5 (41)4 (50).999 Chest X-ray positive for opacities11 (55)7 (58)4 (50).999 Need of O2 therapy16 (80)10 (83)6 (75).999Laboratory Tests on Admission - median (IQR) WBC, cells/μL5440 (3735--7995)4485 (3570--7345)7150 (4830--9825).164 Lymphocytes, %20 (7--24)22 (11--24)7 (6--23).113 Platelets, cells/μL181 (121--227)181 (121--206)164 (108--311).877 T CD4+, cells/μL501 (301--860)528 (429--802)467 (234--1315).713 T CD4/CD8 ratio1.92 (1.21--2.9)2.04 (1.21--2.09)1.62 (1.39--1.92).624 Creatininemia, mg/dL0.85 (0.7--1.14)0.8 (0.6--1.14)0.88 (0.72--2.00).440 LDH, U/L243 (188--377)312 (178--399)243 (213--264).643 C reactive protein, mg/dL (n.v. \< 2.9)90 (17--140)93 (17--130)76 (27--146).877 Interleukin- 6, pg/mL56 (24--112)32 (25--112)68 (22--109).868 D-dimers, μg/L (v.n \< 500)895 (477--1692)741 (381--921)1692 (855--5430)**.030** NT-pro-BNP, pg/mL (v.n. \< 166)122 (104--521)115 (104--353)337 (105--5045).327 HS-Troponin I, ng/mL (v.n. \< 71)10 (5--21)8.4 (6.4--11)20 (5--34).266Arterial gas analysis on admission - median (IQR) pH7.46 (7.44--7.51)7.46 (7.44--7.49)7.47 (7.41--7.53).999 pO279 (64--89)76 (67--85)82 (64--91).699 pC0233 (30--39)34 (30--40)32 (30--35).487 P/F ratio343 (204--380)343 (210--380)328 (186--373).836Antiviral Treatment - n (%) Lopinavir/r9 (45)7 (58)2 (25).197 Hydroxycloroquine13 (65)9 (75)4 (50).356 Azithromicin11 (55)7 (58)4 (50).999Days of Antiviral Treatment, median (IQR)8 (5--9)8 (6--12)5 (5--9).101Other Antibiotic treatment - n (%)10 (50)7 (58)3 (37).650Tocilizumab treatment (8 mg/Kg) - n (%)5 (26)4 (36)1 (12).338Enoxaparin Treatment - n (%)17 (85)10 (83)7 (87).999Enoxaparin, mg - median (IQR)80 (80--120)80 (80--120)80 (40--120).337Days of Enoxaparin - median (IQR)11 (6--13)11 (6--18)9 (2--13).141Days of Disease until CTPA, median (IQR)25 (14--31)25 (15--28)23 (14--34).817Need of 10 lt/min of O2 or NIV/IV - n (%)8 (40)6 (50)2 (25).373Need of ICU stay/mechanical ventilation - n (%)6 (30)4 (33)2 (25).545Heart rate \>100 bpm when apiretic - n (%)4 (20)1 (8)3 (37).255Atypical chest pain - n (%)2 (10)1 (8)1 (12).999Revised Geneva Score - median (IQR)1.5 (0--5.5)0 (0--3)1 (0--1)**.025**Well\'s Score - median (IQR)1.25 (0--2.75)0.5 (0--2.5)5.5 (2--6).394YEARS algorithm (PE not excluded) - n (%)14 (70)7 (58)7 (87).325[^2]

Notably, the predictors of APE were higher D-Dimer levels (*p* = .*030*), and higher Revised Geneva Score (*p* = .*025*). Age, major comorbidities, high oxygen flux requirement or need for invasive mechanical ventilation, Well\'s Score, and the YEARS algorithm were not associated with APE. In fact, among the eight patients presenting APE, one was a 32-year-old female with no comorbidities who did not require oxygen supplementation.

Remarkably, all patients except one developed EPA despite prophylactic treatment with enoxaparin.

To conclude, the occurrence of APE in our case series was higher than expected. Of note, APE was detected even in young patients with mild symptoms; conversely, critically ill patients did not necessarily show signs of embolism, suggesting other pathogenetic mechanisms apart from blood clotting.

While thrombotic complications in the course of COVID-19 pneumonia are well documented, more needs to be known about the exact mechanism behind the coagulopathy, which could possibly be a result of direct viral damage to endothelial cells, but also could relate to the disseminated intravascular coagulation (DIC) activated in the course of viral sepsis ([@bib0015]).

As APE diagnosis is essential for establishing the appropriate dosage and length of anticoagulant treatment, the identification of specific COVID-related predictors is warranted.
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[^2]: Legend: IQR = interquartile range; yr = years; COPD = chronic obstructive pulmonary disease; CTPA = Computed Tomography Pulmonary Angiography; NIV = non-invasive ventilation; IV = invasive ventilation; ICU = intensive care unit; PE = pulmonary embolism.
